Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests

v3.22.2.2
Non-Controlling Interests
9 Months Ended
Sep. 30, 2022
Non-Controlling Interests  
Non-Controlling Interests

10. Non-Controlling Interests

Non-controlling interests in consolidated entities are as follows:

​

​

​

​

​

​

​

​

​

​

​

For the Nine Months Ended

    

    

​

    

    

 

​

September 30, 2022

​

As of September 30, 2022

​

​

 

​

Net loss attributable to

​

Non-controlling interests

​

Non-controlling

 

($ in thousands)

non-controlling interests

​

in consolidated entities

​

ownership

 

Urica

$

(870)

​

$

(1,182)

 

34.5

%

Aevitas

 

(475)

​

 

(5,637)

 

45.2

%

Avenue 2

 

(2,984)

​

 

(31)

 

81.8

%

Baergic

 

(261)

​

 

(2,434)

 

39.0

%

Cellvation

 

(161)

​

 

(1,759)

 

21.7

%

Checkpoint 1

 

(33,568)

​

 

(1,078)

 

80.7

%

Coronado SO

 

—

​

 

(290)

 

13.0

%

Cyprium

 

(732)

​

 

(3,272)

 

29.0

%

Helocyte

 

(283)

​

 

(5,787)

 

17.9

%

JMC

 

(7,355)

​

 

11,189

 

42.7

%

Mustang 2

 

(49,944)

​

 

52,225

 

81.2

%

Oncogenuity

 

(187)

​

 

(1,495)

 

27.4

%

Tamid

 

(21)

​

 

(768)

 

22.8

%

Total

$

(96,841)

​

$

39,681

 

  

​

​

​

​

​

​

​

​

​

​

​

​

For the Year Ended

​

    

​

​

    

 

​

December 31, 2021

​

As of December 31, 2021

​

​

 

​

Net loss attributable to 

​

Non-controlling interests 

​

Non-controlling 

 

($ in thousands)

non-controlling interests

    

 in consolidated entities

    

 ownership

 

Urica

​

(1,353)

​

$

(1,795)

 

34.5

%

Aevitas

​

(901)

​

 

(5,060)

 

45.9

%

Avenue 2

​

(2,909)

​

 

2,830

 

82.0

%

Baergic

​

(39)

​

 

(2,086)

 

39.0

%

Cellvation

​

(131)

​

 

(1,544)

 

21.7

%

Checkpoint 1

​

(39,226)

​

 

24,238

 

81.5

%

Coronado SO

​

—

​

 

(290)

 

13.0

%

Cyprium

​

(807)

​

 

(2,204)

 

29.8

%

Helocyte

​

(89)

​

 

(5,529)

 

18.3

%

JMC

​

(5,652)

​

 

17,498

 

41.6

%

Mustang 2

​

(48,518)

​

 

93,009

 

82.7

%

Oncogenuity

​

(497)

​

 

(1,124)

 

24.9

%

Tamid

​

(1)

​

 

(740)

 

22.8

%

Total

$

(100,123)

​

$

117,203

 

​

​

​

Note 1:

Checkpoint and JMC are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Class A Preferred Shares which provide super-majority voting rights.